Wall Street Zen upgraded shares of Guardian Pharmacy Services (NYSE:GRDN – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
A number of other research firms have also recently commented on GRDN. KeyCorp started coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, September 22nd. They set an “overweight” rating and a $52.00 target price for the company. Oppenheimer upped their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Guardian Pharmacy Services from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, November 9th. Finally, Truist Financial lifted their price objective on Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.57.
Check Out Our Latest Research Report on GRDN
Guardian Pharmacy Services Stock Performance
Shares of NYSE GRDN opened at $49.35 on Friday. The firm has a market cap of $3.12 billion, a PE ratio of 42.18, a PEG ratio of 2.58 and a beta of 0.06. The firm has a fifty day moving average of $42.65 and a 200 day moving average of $38.87. Guardian Pharmacy Services has a one year low of $26.34 and a one year high of $50.58.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The business had revenue of $371.07 million for the quarter, compared to the consensus estimate of $365.76 million. Guardian Pharmacy Services had a net margin of 5.13% and a return on equity of 30.29%. On average, equities analysts predict that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.
Institutional Trading of Guardian Pharmacy Services
Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its holdings in Guardian Pharmacy Services by 53.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,050 shares of the company’s stock valued at $43,000 after purchasing an additional 366 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Guardian Pharmacy Services by 105.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 2,390 shares of the company’s stock worth $97,000 after buying an additional 1,229 shares during the last quarter. Voya Investment Management LLC acquired a new stake in shares of Guardian Pharmacy Services during the 3rd quarter worth approximately $238,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Guardian Pharmacy Services during the 2nd quarter valued at approximately $335,000. Finally, Arizona State Retirement System raised its position in shares of Guardian Pharmacy Services by 53.0% during the 2nd quarter. Arizona State Retirement System now owns 8,393 shares of the company’s stock valued at $351,000 after buying an additional 2,907 shares during the period.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc. provides pharmacy services to people living in long-term care and residential care settings. Its customers include assisted living and skilled nursing communities, behavioral health facilities, and other group-living providers. The company supplies prescription medications and offers medication packaging, delivery, consulting, and clinical support. Its services are designed to help care providers manage residents’ medication needs and support continuity of care. Founded in 2004, Guardian operates a network of pharmacies serving communities across the United States.
Further Reading
- Five stocks we like better than Guardian Pharmacy Services
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
